# US 2026/0055063 A1 · Compound containing benzene ring and application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0055063 A1
- Document ID: US20260055063A1
- Status: Published application
- Kind: A1
- Application number: 19/379,029
- Filed: 2025-11-04
- Published: 2026-02-26
- Earliest claimed: 2019-11-29
- Assignees: Wuhan Ll Science and Technology Development Co., Ltd.
- Applicants: Wuhan Ll Science and Technology Development Co., Ltd.
- Inventors: Jun LOU; Yongkai CHEN; Yihan ZHANG; Xiaodan GUO; Lina QIAN; Li LIU; Wei PENG; Fei RONG; Chaodong WANG
- Web page: https://patentgrep.com/patent/US20260055063A1

## CPC

- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- C07D 231/56: Benzopyrazoles; Hydrogenated benzopyrazoles
- A61P 11/14: Antitussive agents
- C07D 209/44: Iso-indoles; Hydrogenated iso-indoles
- C07D 235/18: with aryl radicals directly attached in position 2
- C07D 235/24: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D 249/18: Benzotriazoles
- C07D 261/20: condensed with carbocyclic rings or ring systems
- C07D 263/57: Aryl or substituted aryl radicals
- C07D 277/62: Benzothiazoles
- C07D 277/64: with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- C07D 307/79: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 413/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D 487/04: Ortho-condensed systems
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

A compound containing a benzene ring as shown in formula I, a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, an isotopic compound thereof, a crystal form thereof, a nitrogen oxide thereof, and a solvate thereof or a solvate of the pharmaceutically acceptable salt thereof are provided. The compound has high P2X4 antagonistic activity, good selectivity, low toxicity and good metabolic stability.

## Claims

### Claim 1

A method for treating diseases comprising administering a therapeutically effective amount of substance A to a patient;
the diseases are urinary tract diseases, respiratory diseases, pain, autoimmune diseases, inflammation, Alzheimer's disease, Parkinson's disease, epilepsy, arthritis, neurodegeneration, traumatic brain injury, myocardial infarction, rheumatoid arthritis, atherosclerosis, inflammatory bowel disease, gastrointestinal dysfunction, heart failure, hypertension, or endometriosis;
substance A is a compound containing a benzene ring represented by formula I, or a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, an isotope compound thereof, a crystalline form thereof, a nitrogen oxide thereof or a solvate thereof, or a solvate of a pharmaceutically acceptable salt thereof;
wherein,
is a benzene ring;
is a “5 membered heteroaryl ring containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” or a “5 membered heteroalkenyl ring containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S”;
R1 is
R1-1 is C1-C6 alkyl,
R3 is
n is 0, 1, 2 or 3;
R3-1 is independently halogen, hydroxyl, C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, or C1-C6 alkoxy substituted with C1-C6 alkoxy;
R3-2 is C3-C6 cycloalkyl substituted with one or more R3-2-1, “5-6 membered heterocycloalkyl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted with one or more R3-2-2 or “5-6 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted with one or more R3-2-3;
R3-2-1, R3-2-2 and R3-2-3 are independently halogen, hydroxyl, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, or C1-C6 alkoxy substituted with C1-C6 alkoxy;
m is 0, 1 or 2;
R2 is oxo, halogen, cyano, C1-C10 alkyl, C1-C10 alkyl substituted with one or more R2-1, C2-C6 alkenyl, C2-C6 alkenyl substituted with one or more R2-7, C3-C6 cycloalkyl, C3-C6 cycloalkyl substituted with one or more R2-3, “5-6 membered heterocycloalkyl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, “4 membered heterocycloalkyl containing 1 heteroatom selected from one of N, O and S”, “4-6 membered heterocycloalkyl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted with one or more R2-6, phenyl, phenyl substituted with one or more R2-4, “5-6 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, “5-6 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted with one or more R2-5, or —(C═O)—R2-2;
R2-1 is independently hydroxyl, halogen, C3-C6 cycloalkyl, C3-C6 cycloalkyl substituted with one or more R2-1-8, “4-6 membered heterocycloalkyl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, “4-6 membered heterocycloalkyl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted with one or more R2-1-7, phenyl, phenyl substituted with one or more R2-1-1, “5-6 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, “5-6 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted with one or more R2-1-6, —OR2-1-2, —N(R2-1-3)(R2-1-4), or —S(═O)2—R2-1-5;
R2-1-1, R2-1-6, R2-1-7 and R2-1-8 are independently oxo, hydroxyl, amino, carboxyl, halogen, —CN, C1-C6 alkyl, C1-C6 alkyl substituted with one or more halogen, —OR2-1-1-1, or —N(R2-1-1-2)(R2-1-1-3); R2-1-1-1, R2-1-1-2 and R2-1-1-3 are independently C1-C6 alkyl;
R2-1-2 is independently C1-C6 alkyl or C3-C6 cycloalkyl;
R2-1-3 and R2-1-4 are independently hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl;
R2-1-5 is independently C1-C6 alkyl or C3-C6 cycloalkyl;
R2-3 and R2-6 are independently C1-C6 alkyl;
R2-4 and R2-5 are independently halogen, hydroxyl, —N(R2-4-1)(R2-4-2) or C1-C6 alkoxy; R2-4-1 and R2-4-2 are independently hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl;
R2-7 is independently halogen;
R2-2 is C1-C6 alkyl, C3-C6 cycloalkyl, phenyl or phenyl substituted with one or more R2-2-1; R2-2-1 is independently halogen.

### Claim 2 (depends on 1)

The method for treating diseases according to claim 1, wherein
is a benzene ring
and/or,
is a “5 membered heteroaryl ring containing 1 or 2 heteroatoms selected from one or more of N, O and S” or a “5 membered heteroalkenyl ring containing 1 or 2 heteroatoms selected from one or more of N, O and S”;
and/or, R1 is
and/or, R3 is
n is 1; R3-1 is halogen, C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, or C1-C6 alkoxy substituted with C1-C6 alkoxy; R3-2 is C3-C6 cycloalkyl substituted with one or more R3-2-1, or “5-6 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted with one or more R3-2-3; R3-2-1 and R3-2-3 are independently halogen or hydroxyl;
and/or, R2 is halogen, cyano, C1-C10 alkyl, C1-C10 alkyl substituted with one or more R2-1, C2-C6 alkenyl, C2-C6 alkenyl substituted with one or more R2-7, C3-C6 cycloalkyl, C3-C6 cycloalkyl substituted with one or more R2-3, “5-6 membered heterocycloalkyl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, “4 membered heterocycloalkyl containing 1 heteroatom selected from one of N, O and S”, “4-6 membered heterocycloalkyl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted with one or more R2-6, phenyl substituted with one or more R2-4, or —(C═O)—R2-2;
R2-1 is independently hydroxyl, halogen, C3-C6 cycloalkyl, C3-C6 cycloalkyl substituted with one or more R2-1-8, “4-6 membered heterocycloalkyl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, phenyl substituted with one or more R2-1-1, “5-6 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted with one or more R2-1-6, —OR2-1-2, —N(R2-1-3)(R2-1-4) or —S(═O)2—R2-1-5; R2-1-1, R2-1-6 and R2-1-8 are independently hydroxyl, amino, halogen, —CN, C1-C6 alkyl, C1-C6 alkyl substituted with one or more halogen, —OR2-1-1-1, or —N(R2-1-1-2)(R2-1-1-3); R2-1-1-1, R2-1-1-2 and R2-1-1-3 are independently C1-C6 alkyl; R2-1-2 is independently C1-C6 alkyl or C3-C6 cycloalkyl; R2-1-3 and R2-1-4 are independently hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl; R2-1-5 is independently C1-6 alkyl or C3-C6 cycloalkyl; R2-3 and R2-6 are independently C1-C6 alkyl; R2-4 is independently halogen; R2-7 is independently halogen; R2-2 is C1-C6 alkyl, C3-C6 cycloalkyl, phenyl or phenyl substituted with one or more R2-2-1; R2-2-1 is independently halogen.

### Claim 3 (depends on 2)

The method for treating diseases according to claim 2, wherein
is
and/or, R3 is
n is 1; R3-1 is halogen;
and/or, R2 is C1-C10 alkyl, C1-C10 alkyl substituted with one R2-1, or C3-C6 cycloalkyl; R2-1 is independently halogen, C3-C6 cycloalkyl, phenyl substituted with one or more R2-1-1, “5-6 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted with one or more R2-1-6, or —OR2-1-2; R2-1-1 and R2-1-6 are independently amino, halogen, —CN, C1-C6 alkyl, C1-C6 alkyl substituted with one or more halogen, or —OR2-1-1-1; R2-1-1-1 is independently C1-C6 alkyl; R2-1-2 is C1-C6 alkyl.

### Claim 4 (depends on 1)

The method for treating diseases according to claim 1, wherein
is a benzene ring;
is a “5 membered heteroaryl ring containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” or a “5 membered heteroalkenyl ring containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S”;
R1 is
R1-1 is-C1-C6 alkyl,
R3 is
n is 0, 1, 2 or 3;
R3-1 is independently halogen, hydroxyl, C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, or C1-C6 alkoxy substituted with C1-C6 alkoxy;
R3-2 is C3-C6 cycloalkyl substituted with one or more R3-2-1, “5-6 membered heterocycloalkyl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted with one or more R3-2-2, or “5-6 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted with one or more R3-2-3;
R3-2-1, R3-2-2 and R3-2-3 are independently halogen, hydroxyl, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, or C1-C6 alkoxy substituted with C1-C6 alkoxy;
m is 0 or 1;
R2 is oxo, cyano, C1-C10 alkyl, C1-C10 alkyl substituted with one or more R2-1, C3-C6 cycloalkyl, C3-C6 cycloalkyl substituted with one or more R2-3, “5-6 membered heterocycloalkyl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, phenyl, phenyl substituted with one or more R2-4, “5-6 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, “5-6 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted with one or more R2-5, or —(C═O)—R2-2;
R2-1 is independently hydroxyl, halogen, C3-C6 cycloalkyl, C3-C6 cycloalkyl substituted with one or more R2-1-8, “4-6 membered heterocycloalkyl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, “4-6 membered heterocycloalkyl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted with one or more R2-1-7, phenyl, phenyl substituted with one or more R2-1-1, “5-6 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, “5-6 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted with one or more R2-1-6, —OR2-1-2, —N(R2-1-3)(R2-1-4), or —S(═O)2—R2-1-5;
R2-1-1, R2-1-6, R2-1-7 and R2-1-8 are independently oxo, hydroxyl, amino, carboxyl, halogen, —CN, C1-C6 alkyl, C1-C6 alkyl substituted with one or more halogen, —OR2-1-1-1, or —N(R2-1-1-2)(R2-1-1-3); R2-1-1-1, R2-1-1-2 and R2-1-1-3 are independently C1-C6 alkyl;
R2-1-2 is independently C1-C6 alkyl or C3-C6 cycloalkyl;
R2-1-3 and R2-1-4 are independently hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl;
R2-1-5 is independently C1-C6 alkyl or C3-C6 cycloalkyl;
R2-3 is independently C1-C6 alkyl;
R2-4 and R2-5 are independently halogen, hydroxyl, —N(R2-4-1)(R2-4-2) or C1-C6 alkoxy; R2-4-1 and R2-4-2 are independently hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl;
R2-2 is C1-C6 alkyl, C3-C6 cycloalkyl, phenyl or phenyl substituted with one or more R2-2-1; R2-2-1 is independently halogen.

### Claim 5 (depends on 1)

The method for treating diseases according to claim 1, wherein the compound containing a benzene ring represented by formula I is a compound represented by scheme 1, scheme 2, scheme 3, scheme 4, scheme 5, or scheme 6:
scheme 1:
is a benzene ring;
is a “5 membered heteroaryl ring containing 1 or 2 heteroatoms selected from one or more of N, O and S”;
R1 is
R3 is
n is 1;
R3-1 is halogen;
m is 0 or 1;
R2 is cyano, C1-C10 alkyl, C1-C10 alkyl substituted with one or more R2-1, C3-C6 cycloalkyl, C3-C6 cycloalkyl substituted with one or more R2-3, phenyl substituted with one or more R2-4, or —(C═O)—R2-2;
R2-1 is independently hydroxyl, halogen, C3-C6 cycloalkyl, phenyl substituted with one or more R2-1-1, “5-6 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted with one or more R2-1-6, —OR2-1-2, —N(R2-1-3)(R2-1-4), or —S(═O)2—R2-1-5;
R2-1-1 and R2-1-6 are independently hydroxyl, halogen, —OR2-1-1-1 or —N(R2-1-1-2)(R2-1-1-3); R2-1-1-1, R2-1-1-2 and R2-1-1-3 are independently C1-C6 alkyl;
R2-1-2 is independently C1-C6 alkyl or C3-C6 cycloalkyl;
R2-1-3 and R2-1-4 are independently hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl;
R2-1-5 is independently C1-C6 alkyl or C3-C6 cycloalkyl;
R2-3 is independently C1-C6 alkyl;
R2-4 is independently halogen;
R2-2 is C1-C6 alkyl, C3-C6 cycloalkyl, phenyl or phenyl substituted with one or more R2-2-1; R2-2-1 is independently halogen;
scheme 2:
R1 is
R3 is
n is 1;
R3-1 is halogen;
R2 is C1-C10 alkyl, C1-C10 alkyl substituted with one R2-1, or C3-C6 cycloalkyl;
R2-1 is independently halogen, C3-C6 cycloalkyl, phenyl substituted with one or more R2-1-1, or —OR2-1-2; R2-1-1 is halogen; R2-1-2 is C1-C6 alkyl;
scheme 3:
is a benzene ring;
is a “5 membered heteroaryl ring containing 1 or 2 heteroatoms selected from one or more of N, O and S” or a “5 membered heteroalkenyl ring containing 1 or 2 heteroatoms selected from one or more of N, O and S”;
R1 is
R1-1 is C1-C6 alkyl;
R3 is
n is 1;
R3-1 is halogen, C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, or C1-C6 alkoxy substituted with C1-C6 alkoxy;
R3-2 is C3-C6 cycloalkyl substituted with one or more R3-2-1, or “5-6 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted with one or more R3-2-3;
R3-2-1 and R3-2-3 are independently halogen or hydroxyl;
m is 0, 1 or 2;
R2 is halogen, cyano, C1-C10 alkyl, C1-C10 alkyl substituted with one or more R2-1, C2-C6 alkenyl, C2-C6 alkenyl substituted with one or more R2-7, C3-C6 cycloalkyl, C3-C6 cycloalkyl substituted with one or more R2-3, “5-6 membered heterocycloalkyl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, “4 membered heterocycloalkyl containing 1 heteroatom selected from one of N, O and S”, “4-6 membered heterocycloalkyl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted with one or more R2-6, phenyl substituted with one or more R2-4, or —(C═O)—R2-2;
R2-1 is independently hydroxyl, halogen, C3-C6 cycloalkyl, “4-6 membered heterocycloalkyl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, phenyl substituted with one or more R2-1-1, “5-6 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted with one or more R2-1-6, —OR2-1-2, —N(R2-1-3)(R2-1-4), or —S(═O)2—R2-1-5;
R2-1-1 and R2-1-6 are independently hydroxyl, amino, halogen, —CN, C1-C6 alkyl, C1-C6 alkyl substituted with one or more halogen, —OR2-1-1-1 or —N(R2-1-1-2)(R2-1-1-3); R2-1-1-1, R2-1-1-2 and R2-1-1-3 are independently C1-C6 alkyl;
R2-1-2 is independently C1-C6 alkyl or C3-C6 cycloalkyl;
R2-1-3 and R2-1-4 are independently hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl;
R2-1-5 is independently C1-C6 alkyl or C3-C6 cycloalkyl;
R2-3 and R2-6 are independently C1-C6 alkyl;
R2-4 is independently halogen;
R2-7 is independently halogen;
R2-2 is C1-C6 alkyl, C3-C6 cycloalkyl, phenyl or phenyl substituted with one or more R2-2-1; R2-2-1 is independently halogen;
scheme 4:
R1 is
R3 is
n is 1;
R3-1 is halogen;
R2 is C1-C10 alkyl, C1-C10 alkyl substituted with one R2-1, or C3-C6 cycloalkyl;
R2-1 is independently halogen, C3-C6 cycloalkyl, phenyl substituted with one or more R2-1-1, or —OR2-1-2; R2-1-1 is independently amino, halogen, —CN, C1-C6 alkyl, C1-C6 alkyl substituted with one or more halogen or —OR2-1-1-1; R2-1-1-1 is independently C1-C6 alkyl; R2-1-2 is C1-C6 alkyl;
scheme 5:
is a benzene ring;
is a “5 membered heteroaryl ring containing 1 or 2 heteroatoms selected from one or more of N, O and S” or a “5 membered heteroalkenyl ring containing 1 or 2 heteroatoms selected from one or more of N, O and S”;
R1 is
R1-1 is C1-C6 alkyl;
R3 is
n is 1;
R3-1 is halogen, C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, or C1-C6 alkoxy substituted with C1-C6 alkoxy;
R3-2 is C3-C6 cycloalkyl substituted with one or more R3-2-1, or “5-6 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted with one or more R3-2-3;
R3-2-1 and R3-2-3 are independently halogen or hydroxyl;
m is 0, 1 or 2;
R2 is halogen, cyano, C1-C10 alkyl, C1-C10 alkyl substituted with one or more R2-1, C2-C6 alkenyl, C2-C6 alkenyl substituted with one or more R2-7, C3-C6 cycloalkyl, C3-C6 cycloalkyl substituted with one or more R2-3, “5-6 membered heterocycloalkyl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, “4 membered heterocycloalkyl containing 1 heteroatom selected from one of N, O and S”, “4-6 membered heterocycloalkyl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted with one or more R2-6, phenyl substituted with one or more R2-4, or —(C═O)—R2-2;
R2-1 is independently hydroxyl, halogen, C3-C6 cycloalkyl, C3-C6 cycloalkyl substituted with one or more R2-1-8, “4-6 membered heterocycloalkyl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, phenyl substituted with one or more R2-1-1, “5-6 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted with one or more R2-1-6, —OR2-1-2, —N(R2-1-3)(R2-1-4), or —S(═O)2—R2-1-5;
R2-1-1, R2-1-6 and R2-1-8 are independently hydroxyl, amino, halogen, —CN, C1-C6 alkyl, C1-C6 alkyl substituted with one or more halogen, —OR2-1-1-1, or —N(R2-1-1-2)(R2-1-1-3); R2-1-1-1, R2-1-1-2 and R2-1-1-3 are independently C1-C6 alkyl;
R2-1-2 is independently C1-C6 alkyl or C3-C6 cycloalkyl;
R2-1-3 and R2-1-4 are independently hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl;
R2-1-5 is independently C1-C6 alkyl or C3-C6 cycloalkyl;
R2-3 and R2-6 are independently C1-C6 alkyl;
R2-4 is independently halogen;
R2-7 is independently halogen;
R2-2 is C1-C6 alkyl, C3-C6 cycloalkyl, phenyl or phenyl substituted with one or more R2-2-1; R2-2-1 is independently halogen;
scheme 6:
R1 is
R3 is
n is 1;
R3-1 is halogen;
R2 is C1-C10 alkyl, C1-C10 alkyl substituted with one R2-1, or C3-C6 cycloalkyl;
R2-1 is independently halogen, C3-C6 cycloalkyl, phenyl substituted with one or more R2-1-1, “5-6 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted with one or more R2-1-6, or —OR2-1-2; R2-1-1 and R2-1-6 are independently amino, halogen, —CN, C1-C6 alkyl, C1-C6 alkyl substituted with one or more halogen, or —OR2-1-1-1; R2-1-1-1 is independently C1-C6 alkyl; R2-1-2 is C1-C6 alkyl.

### Claim 6 (depends on 1)

The method for treating diseases according to claim 1, wherein, when
is a “5 membered heteroaryl ring containing 1 or 2 heteroatoms selected from one or more of N, O and S”, the “5 membered heteroaryl ring containing 1 or 2 heteroatoms selected from one or more of N, O and S” is a “5 membered heteroaryl ring containing 1 or 2 heteroatoms selected from N”;
and/or, when
is a “5 membered heteroalkenyl ring containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, the “5 membered heteroalkenyl ring containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” is a “5 membered heteroalkenyl ring containing 1 or 2 heteroatoms selected from N”;
and/or, when R1-1 is C1-C6 alkyl, the C1-C6 alkyl is C1-C4 alkyl;
and/or, when n is 1 or 2, R3-1 is independently located in the ortho-, meta- or para-position relative to
and/or, when R3-1 is independently halogen, the halogen is fluorine, chlorine, bromine or iodine;
and/or, when R3-1 is C1-C6 alkyl, the C1-C6 alkyl is C1-C4 alkyl;
and/or, when R3-1 is C1-C6 alkoxy, the C1-C6 alkoxy is C1-C4 alkoxy;
and/or, when R3-1 is C1-C6 alkoxy substituted with C1-C6 alkoxy, the C1-C6 alkoxy is C1-C4 alkoxy;
and/or, when R3-2 is C3-C6 cycloalkyl substituted with one or more R3-2-1, the C3-C6 cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl;
and/or, when R3-2-3 is halogen, the halogen is fluorine, chlorine, bromine or iodine;
and/or, when R3-2 is “5-6 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted with one or more R3-2-3, the “5-6 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” is “5-6 membered heteroaryl containing 1 or 2 heteroatoms selected from N”;
and/or, when R2 is halogen, the halogen is fluorine, chlorine, bromine or iodine;
and/or, when R2 is C1-C10 alkyl, the C1-C10 alkyl is C1-C6 alkyl;
and/or, when R2 is C1-C10 alkyl substituted with one or more R2-1, the C1-C10 alkyl is C1-C6 alkyl;
and/or, when R2-1 is independently halogen, the halogen is fluorine, chlorine, bromine or iodine;
and/or, when R2-1 is independently C3-C6 cycloalkyl, the C3-C6 cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl;
and/or, when R2-1 is C3-C6 cycloalkyl substituted with one or more R2-1-8, the C3-C6 cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl;
and/or, when R2-1 is “4-6 membered heterocycloalkyl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, the “4-6 membered heterocycloalkyl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” is “5 or 6 membered heterocycloalkyl containing 1 or 2 heteroatoms selected from one or more of N, O and S”;
and/or, when R2-1 is independently “5-6 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted with one or more R2-1-6, the “5-6 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” is “5-6 membered heteroaryl containing 1 heteroatom selected from one or more of N, O and S”;
and/or, R2-1-1 is independently located in the ortho-, meta- or para-position relative to phenyl;
and/or, R2-1-6 is independently located in the ortho-, meta- or para-position relative to 6 membered heteroaryl;
and/or, R2-1-6 is independently located in the ortho- or meta-position relative to 5 membered heteroaryl;
and/or, when R2-1-1 is independently halogen, the halogen is fluorine, chlorine, bromine or iodine;
and/or, when R2-1-1 is C1-C6 alkyl, the C1-C6 alkyl is C1-C4 alkyl;
and/or, when R2-1-1 is C1-C6 alkyl substituted with one or more halogen, the halogen is fluorine, chlorine, bromine or iodine;
and/or, when R2-1-1 is C1-C6 alkyl substituted with one or more halogen, the C1-C6 alkyl is C1-C4 alkyl;
and/or, when R2-1-6 is independently halogen, the halogen is fluorine, chlorine, bromine or iodine;
and/or, when R2-1-1-1, R2-1-1-2 and R2-1-1-3 are independently C1-C6 alkyl, the C1-C6 alkyl is C1-C4 alkyl;
and/or, when R2-1-2 is independently C1-C6 alkyl, the C1-C6 alkyl is C1-C4 alkyl;
and/or, when R2-1-2 is independently C3-C6 cycloalkyl, the C3-C6 cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl;
and/or, when R2-1-3 and R2-1-4 are independently C1-C6 alkyl, the C1-C6 alkyl is C1-C4 alkyl;
and/or, when R2-1-3 and R2-1-4 are independently C3-C6 cycloalkyl, the C3-C6 cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl;
and/or, when R2-1-5 is independently C1-C6 alkyl, the C1-C6 alkyl is C1-C4 alkyl;
and/or, when R2-1-5 is independently C3-C6 cycloalkyl, the C3-C6 cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl;
and/or, when R2 is C3-C6 cycloalkyl, the C3-C6 cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl;
and/or, when R2 is C3-C6 cycloalkyl substituted with one or more R2-3, the C3-C6 cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl;
and/or, when R2-3 is independently C1-C6 alkyl, the C1-C6 alkyl is C1-C4 alkyl;
and/or, when R2 is C2-C6 alkenyl, the C2-C6 alkenyl is C2-C4 alkenyl;
and/or, when R2 is C2-C6 alkenyl substituted with one or more R2-7, the C2-C6 alkenyl is C2-C4 alkenyl;
and/or, when R2-7 is halogen, the halogen is fluorine, chlorine, bromine or iodine;
and/or, when R2 is “4 membered heterocycloalkyl containing 1 heteroatom selected from one of N, O and S”, the “4 membered heterocycloalkyl containing 1 heteroatom selected from one of N, O and S” is oxetanyl;
and/or, when R2-6 is C1-C6 alkyl, the C1-C6 alkyl is C1-C4 alkyl;
and/or, when R2 is “4-6 membered heterocycloalkyl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted with one or more R2-6, the “4-6 membered heterocycloalkyl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” is “4-6 membered heterocycloalkyl containing 1 heteroatom selected from one of N, O and S”;
and/or, R2-4 is independently located in the ortho-, meta- or para-position relative to phenyl;
and/or, when R2-4 is independently halogen, the halogen is fluorine, chlorine, bromine or iodine;
and/or, when R2-2 is independently C1-C6 alkyl, the C1-C6 alkyl is C1-C4 alkyl;
and/or, when R2-2 is C3-C6 cycloalkyl, the C3-C6 cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl;
and/or, R2-2-1 is independently located in the ortho-, meta- or para-position relative to phenyl;
and/or, when R2-2-1 is independently halogen, the halogen is fluorine, chlorine, bromine or iodine.

### Claim 7 (depends on 6)

The method for treating diseases according to claim 6, wherein, when
is a “5 membered heteroaryl ring containing 1 or 2 heteroatoms selected from one or more of N, O and S”, the “5 membered heteroaryl ring containing 1 or 2 heteroatoms selected from one or more of N, O and S” is a pyrrole ring, a pyrazole ring or an imidazole ring;
and/or, when
is a “5 membered heteroalkenyl ring containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, the “5 membered heteroalkenyl ring containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” is a 2,5-dihydropyrrole ring;
and/or, when R1-1 is C1-C6 alkyl, the C1-C6 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl;
and/or, when R3-1 is independently halogen, the halogen is chlorine;
and/or, when n is 1 or 2, R3-1 is independently located in the ortho-position relative to
and/or, when R3-1 is C1-C6 alkyl, the C1-C6 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl;
and/or, when R3-1 is C1-C6 alkoxy, the C1-C6 alkoxy is methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy or tert-butoxy;
and/or, when R3-1 is C1-C6 alkoxy substituted with C1-C6 alkoxy, the C1-C6 alkoxy is methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy or tert-butoxy;
and/or, when R3-2 is C3-C6 cycloalkyl substituted with one or more R3-2-1, the C3-C6 cycloalkyl substituted with one R3-2-1 is
and/or, when R3-2-3 is halogen, the halogen is chlorine;
and/or, when R3-2 is “5-6 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted with one or more R3-2-3, the “5-6 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” is pyridinyl;
and/or, when R2 is halogen, the halogen is chlorine;
and/or, when R2 is C1-C10 alkyl, the C1-C10 alkyl is C1-C5 alkyl;
and/or, when R2 is C1-C10 alkyl substituted with one or more R2-1, the C1-C10 alkyl is C1-C4 alkyl;
and/or, when R2-1 is independently halogen, the halogen is fluorine;
and/or, when R2-1 is “4-6 membered heterocycloalkyl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, the “4-6 membered heterocycloalkyl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” is tetrahydrofuranyl, morpholinyl or tetrahydropyranyl;
and/or, when R2-1 is independently “5-6 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted with one or more R2-1-6, the “5-6 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” is pyridinyl;
and/or, when R2-1-1 is independently halogen, the halogen is fluorine;
and/or, when R2-1-1 is C1-C6 alkyl, the C1-C6 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl;
and/or, when R2-1-1 is C1-C6 alkyl substituted with one or more halogen, the halogen is fluorine;
and/or, when R2-1-1 is C1-C6 alkyl substituted with one or more halogen, the C1-C6 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl;
and/or, when R2-1-6 is independently halogen, the halogen is fluorine;
and/or, when R2-1-1-1, R2-1-1-2 and R2-1-1-3 are independently C1-C6 alkyl, the C1-C6 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl;
and/or, when R2-1-2 is independently C1-C6 alkyl, the C1-C6 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl;
and/or, when R2-1-2 is independently C3-C6 cycloalkyl, the C3-C6 cycloalkyl is cyclopropyl;
and/or, when R2-1-3 and R2-1-4 are independently C1-C6 alkyl, the C1-C6 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl;
and/or, when R2-1-3 and R2-1-4 are independently C3-C6 cycloalkyl, the C3-C6 cycloalkyl is cyclopropyl;
and/or, when R2-1-5 is independently C1-C6 alkyl, the C1-C6 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl;
and/or, when R2-1 is independently C3-C6 cycloalkyl, the C3-C6 cycloalkyl is cyclopropyl;
and/or, when R2 is C3-C6 cycloalkyl, the C3-C6 cycloalkyl is cyclopropyl;
and/or, when R2 is C3-C6 cycloalkyl substituted with one or more R2-3, the C3-C6 cycloalkyl is cyclopropyl;
and/or, when R2-3 is independently C1-C6 alkyl, the C1-C6 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl;
and/or, when R2 is C2-C6 alkenyl, the C2-C6 alkenyl is vinyl or propenyl;
and/or, when R2 is C2-C6 alkenyl substituted with one or more R2-7, the C2-C6 alkenyl is vinyl or propenyl;
and/or, when R2-7 is halogen, the halogen is fluorine;
and/or, when R2 is “4 membered heterocycloalkyl containing 1 heteroatom selected from one of N, O and S”, the “4 membered heterocycloalkyl containing 1 heteroatom selected from one of N, O and S” is oxetan-3-yl;
and/or, when R2-6 is C1-C6 alkyl, the C1-C6 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl;
and/or, when R2 is “4-6 membered heterocycloalkyl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted with one or more R2-6, the “4-6 membered heterocycloalkyl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” is oxetan-3-yl;
and/or, when R2-4 is independently halogen, the halogen is fluorine or chlorine;
and/or, when R2-2 is independently C1-C6 alkyl, the C1-C6 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl;
and/or, when R2-2 is C3-C6 cycloalkyl, the C3-C6 cycloalkyl is cyclopropyl;
and/or, when R2-2-1 is independently halogen, the halogen is fluorine.

### Claim 8 (depends on 7)

The method for treating diseases according to claim 7, wherein,
and/or, when R3-1 is C1-C6 alkoxy substituted with C1-C6 alkoxy, the C1-C6 alkoxy substituted with C1-C6 alkoxy is
and/or, when R3-2 is “5-6 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted with one or more R3-2-3, the “5-6 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted with one R3-2-3 is
and/or, when R2 is C1-C10 alkyl, the C1-C10 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl or
and/or, when R2 is C1-C10 alkyl substituted with one or more R2-1, the C1-C10 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl;
and/or, when R2-1 is “4-6 membered heterocycloalkyl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, the “4-6 membered heterocycloalkyl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” is tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, morpholin-1-yl or tetrahydropyran-4-yl;
and/or, when R2-1 is independently “5-6 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted with one or more R2-1-6, the “5-6 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from one or more of N, O and S” is pyridin-3-yl or pyridin-4-yl;
and/or, when R2-1-1 is C1-C6 alkyl, the C1-C6 alkyl is methyl or isopropyl;
and/or, when R2-1-1 is C1-C6 alkyl substituted with one or more halogen, the C1-C6 alkyl substituted with a plurality of halogen is trifluoromethyl;
and/or, when R2-1-1-1, R2-1-1-2 and R2-1-1-3 are independently C1-C6 alkyl, the C1-C6 alkyl is methyl;
and/or, when R2-1-2 is independently C1-C6 alkyl, the C1-C6 alkyl is methyl or isopropyl;
and/or, when R2-1-3 and R2-1-4 are independently C1-C6 alkyl, the C1-C6 alkyl is methyl or isopropyl;
and/or, when R2-1-5 is independently C1-C6 alkyl, the C1-C6 alkyl is methyl or isopropyl;
and/or, when R2-3 is independently C1-C6 alkyl, the C1-C6 alkyl is methyl, ethyl or isopropyl;
and/or, when R2-6 is C1-C6 alkyl, the C1-C6 alkyl is methyl;
and/or, when R2-2 is independently C1-C6 alkyl, the C1-C6 alkyl is isopropyl.

### Claim 9 (depends on 1)

The method for treating diseases according to claim 1, wherein, the compound containing a benzene ring represented by formula I is any one of the following compounds:

### Claim 10 (depends on 1)

A method for treating diseases mediated at least in part by P2X4, comprising administering a therapeutically effective amount of substance A to a patient; wherein
substance A is the compound containing a benzene ring represented by formula I, or the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, the isotope compound thereof, the crystalline form thereof, the nitrogen oxide thereof or the solvate thereof, or the solvate of the pharmaceutically acceptable salt thereof in claim 1.

### Claim 11 (depends on 1)

Use of substance A in the preparation of a P2X4 receptor antagonist or drug; wherein
substance A is the compound containing a benzene ring represented by formula I, or the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, the isotope compound thereof, the crystalline form thereof, the nitrogen oxide thereof or the solvate thereof, or the solvate of the pharmaceutically acceptable salt thereof in claim 1.

### Claim 12 (depends on 11)

The use according to claim 11, wherein the P2X4 receptor antagonist is for use in vitro;
and/or, the drug is used for the treatment or prevention of urinary tract diseases, respiratory diseases, pain, autoimmune diseases, inflammation, Alzheimer's disease, Parkinson's disease, epilepsy, arthritis, neurodegeneration, traumatic brain injury, myocardial infarction, rheumatoid arthritis, atherosclerosis, inflammatory bowel disease, gastrointestinal dysfunction, heart failure, hypertension, endometriosis in an animal; or, the drug is used for the prevention or treatment of diseases mediated at least in part by P2X4 in an animal.

### Claim 13 (depends on 1)

The method for treating diseases according to claim 1, wherein, the urinary tract diseases are urinary incontinence, overactive bladder, dysuria or cystitis.

### Claim 14 (depends on 1)

The method for treating diseases according to claim 1, wherein, the respiratory diseases are respiratory disorders including idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, asthma, bronchospasm, or cough.

### Claim 15 (depends on 14)

The method for treating diseases according to claim 14, wherein, the cough is chronic cough.

### Claim 16 (depends on 1)

The method for treating diseases according to claim 1, wherein, the pain is inflammatory pain, surgical pain, visceral pain, dental pain, premenstrual pain, central pain, pain resulting from burns, migraine, cluster headache or chronic pain.
